Slide 1: Smarter anesthesia. Safer recoveries.
Smarter anesthesia. Safer recoveries. Senzime AB Philip Siberg
Slide 2: Curare
A deadly, paralyzing poison Curare
Slide 3: Paralytic drugs are now standardized to facilitate safe surgery
Paralytic drugs are now standardized to facilitate safe surgery 100 million Paralyzes patients a year receive patient in ~45 paralytic drugs seconds Recovered 87% of patients are overdosed with Moderate reversal drugs, and 13% underdosed2 Deep ~40% of patients Reversal leave the OR with with residua
Slide 4: Monitoring during anesthesia for improved patient safety: The TetraGraph system
Monitoring during anesthesia for improved patient safety: The TetraGraph neuromuscular monitoring system Algorithm-powered monitoring to secure precise dosing of paralytic drugs empowering clinicians with real-time signals to confidently determine when it's safe for patients to breathe on their own.
Slide 5: Senzime pioneers a radical technology shift enabling more precise monitoring
Senzime pioneers a radical technology shift enabling more precise monitoring of patients under anesthesia >100% 51% 0.3% variability1 variability2 variability2 1980’s 1990’s 2020’s Subjective assessment Legacy monitors Senzime’s TetraGraph Using a peripheral nerve stimulator based on AMG/KMG-technol
Slide 6: EMG-based neuromuscular monitoring increases patient safety and reduces costs
EMG-based neuromuscular monitoring has shown to increase patient safety and reduce costs 0% complications related to post-operative residual block, when used with reversal drugs 70% reduction of the cost of reversal drugs as compared to not using quantitative monitoring. Thilen S. et al 2024: Anesth
Slide 7: Senzime's TetraGraph enables safe, effective, and less costly surgery
Senzime’s TetraGraph enables safe, effective, and less costly surgery Patient is deeply blocked to secure no movement during surgery – accurately monitored by the TetraGraph®
Slide 8: The market we are transforming
The market we are transforming >100 million patients 160,000 Operating Rooms 15,000 Hospitals Estimated that 40-50% of patients >80,000 AMG are monitored with monitors in the some type of market neuromuscular technology. >10,000 Approx. 6-8,000 hospitals EMG monitors in have NMT use, so far equipmen
Slide 9: Nine months 2025: Strong growth and clear steps towards profitability
Nine months 2025: Strong growth and clear steps towards profitability Jan-Sept 2025 revenues (MSEK) 80 1 80% growth in constant currencies 70 2 Sensor deliveries grew 78% 60 50 55 3 Underlying Gross Margin strengthened 40 30 OPEX stable at plan 33 4 20 16 EBITDA improved by 20% 10 21 5 5 11 8 5 0 20
Slide 10: Our installed base of TetraGraph monitors keeps growing
Our installed base of TetraGraph monitors keeps growing… Total delivered units of TetraGraph systems 1 723 (776) TetraGraphs delivered YTD 5,000 4,500 4,000 3,500 3,000 2,500 2,000 1,500 1,000 500 Next-Generation 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2023 2024 2025 9
Slide 11: Driving recurring sales of disposable sensors
…driving recurring sales of disposable sensors Patients monitored with the TetraGraph, accumulated 800,000 700,000 365,535 (205,590) TetraSens sensors sold last 12 months 600,000 500,000 400,000 300,000 200,000 100,000 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2020 2021
Slide 12: Supportive guidelines and practice recommendations of quantitative neuromuscular monitoring
Supportive guidelines and practice recommendations of quantitative neuromuscular monitoring 2025 German 2025 Society of Japanese Anesthetists Society of (DGAI) 2023 Anesthetists European Society (JSA) Anesthetists (ESA) 2021 guidelines 2020 EI Grupo Espanol Canadian de Rehabilitacion 2019 Anesthesio
Slide 13: Integration and Connectivity to industry leaders
Integration and Connectivity to industry leaders TetraGraph Xcom and TetraHub – For seamless data integration Enables connectivity to a wide range of supported external hubs and monitors, ensuring the automatic transmission and display of Latest additions to quantitative TOF monitoring data. The Xco
Slide 14: Selected key US TetraGraph installations in 2025
Selected key US TetraGraph installations in 2025 Pacific North-West Win of the world’s based hospital system leading hospital system Contract includes an initial order of 65 next- Installation of Next-Gen Northern MidWest based generation TetraGraph systems for TetraGraph monitors at multiple hospit
Slide 15: Contract with US Department of Defense
Contract with US Department of Defense “We are proud to be selected as the trusted supplier of our neuromuscular monitoring system to the most prestigious military hospital in the US. This contract is the result of our relentless commitment to patient safety, our scientific leadership, and our organ
Slide 16: Senzime is an industry leader
Senzime is an industry leader TetraGraph utilization of >80% vs. Competitor utilization of <8% 7 YT D 2024 sensors /week/TG 6 YT D 2025 sensors/week/TG 5 4 3 2 1 0 Hospital 1 Hospital 2 Hospital 3 Hospital 4 Hospital 5 These 5 leading accounts (“The 5”) have approx. 350 TetraGraph Units. All are run
Slide 17: Supported by Key Opinion Leaders
Supported by Key Opinion Leaders “Bringing the Next-generation TetraGraph into our community hospital has transformed how we manage neuromuscular block. It has improved patient safety, standardized our practices, and reduced our annual drug spend by more than $100,000.” Dr. Aaron Persinger Anesthesi
Slide 18: Backed by a strong investor base
Backed by a strong investor base Largest shareholders Sept 30, 2025 Crafoord family and the Crafoord Foundation 25,896,551 16,5 Segulah Venture AB, Segulah AB, Segulah Medical Acceleration AB 15,870,271 10,1 Fredrik Rapp 11,879,088 7,6 Fjärde AP-fonden 8,187,000 5,2 Avanza Pension 7,953,362 5,1 Unio
Slide 19: Leading the paradigm-shift of the decade in Operating Rooms across the world
Leading the paradigm-shift of the decade in Operating Rooms across the world Capno- Depth of EMG-based graphy anesthesia Neuromuscular monitoring 1980’s 1990’s 2000’s 2010’s 2020’s Pulse Oximetry & Cerebral AMG-based NMT Oximetry
Slide 20: Safeguard every patient's journey, from anesthesia to recovery
So, join us on our mission to Safeguard every patient's journey, from anesthesia to recovery.